EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Utilization of primary tumor samples for cancer neoantigen discovery

Vid Leko, Eric Groh, Shoshana T Levi, Amy R Copeland, Bradley Sinclair White, Billel Gasmi, Yong Li, Victoria Hill, Devikala Gurusamy, Noam Levin, Sanghyun Peter Kim, Sivasish Sindiri und 7 weitere

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-010993 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Vid Leko und 18 weiteren Autor:innen. Beteiligte Einrichtung: Immune Deficiency Cellular Therapy Program, National Cancer Institute, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Lymphocytes, Tumor-Infiltrating, Colorectal Neoplasms, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural Research Program of the National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The use of tumor-infiltrating T lymphocytes (TIL) that recognize cancer neoantigens has led to lasting remissions in metastatic melanoma and certain cases of metastatic epithelial cancer. For the treatment of the latter, selecting cells for therapy typically involves laborious screening of TIL for recognition of autologous tumor-specific mutations, detected through next-generation sequencing of freshly resected metastatic tumors. Our study explored the feasibility of using archived formalin-fixed, paraffin-embedded (FFPE) primary tumor samples for cancer neoantigen discovery, to potentially expedite this process and reduce the need for resections normally required for tumor sequencing.

Method

Whole-exome sequencing was conducted on matched primary and metastatic colorectal cancer samples from 22 patients. The distribution of metastatic tumor mutations that were confirmed as neoantigens through cognate TIL screening was evaluated in the corresponding primary tumors. Mutations unique to primary tumors were screened for recognition by metastasis-derived TIL and circulating T lymphocytes.

Results

We found that 25 (65.8%) of the 38 validated neoantigens identified in metastatic tumors from 18 patients with colorectal cancer were also present in matched primary tumor samples. This included all 12 neoantigens encoded by putative cancer driver genes, which are generally regarded as superior targets for adoptive cell therapy. The detection rate for other neoantigens, representing mutations without an established role in cancer biology, was 50% (13/26). Gene products encoding neoantigens detected in the primary tumors were not more likely to be clonal or broadly distributed among the analyzed metastatic lesions compared with those undetected in the primary tumors. Additionally, we found that mutations detected only in primary tumor samples did not elicit recognition by metastatic tumor-derived TIL but could elicit specific recognition by the autologous circulating memory T cells.

Conclusions

Our findings indicate that primary FFPE tumor-derived screening libraries could be used to discover most neoantigens present in metastatic tumors requiring treatment. Furthermore, this approach can reveal additional neoantigens not present in resected metastatic tumors, prompting further research to understand their clinical relevance as potential therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmLymphocytes, Tumor-InfiltratingColorectal NeoplasmsNeoplasmsHumansFemaleMaleMutationMiddle AgedExome SequencingHigh-Throughput Nucleotide SequencingAged

Stichwörter der Autor:innen

Adoptive cell therapy - ACTGastrointestinal CancerT cell Receptor - TCRTumor infiltrating lymphocyte - TILTumor mutation burden - TMB

Substanzen

Antigens, Neoplasm

Autor:innen und Institutionen

  • Immune Deficiency Cellular Therapy Program, National Cancer Institute, Bethesda, Maryland, USA.
  • Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA.
  • Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA.
  • Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA PaulRobbins@mail.nih.gov.

Förderung

  • Intramural Research Program of the National Cancer Institute

Zitieren

APA

Leko, V., Groh, E., Levi, S. T., Copeland, A. R., White, B. S., Gasmi, B., Li, Y., Hill, V., Gurusamy, D., Levin, N., Kim, S. P., Sindiri, S., Gartner, J. J., Prickett, T. D., Parkhust, M., Lowery, F. J., Goff, S. L., Rosenberg, S. A., & Robbins, P. (2025). Utilization of primary tumor samples for cancer neoantigen discovery. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010993

Vancouver

Leko V, Groh E, Levi ST, Copeland AR, White BS, Gasmi B, et al. Utilization of primary tumor samples for cancer neoantigen discovery. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010993

BibTeX
@article{Leko2025,
  author = {Leko, Vid and Groh, Eric and Levi, Shoshana T and Copeland, Amy R and White, Bradley Sinclair and Gasmi, Billel and Li, Yong and Hill, Victoria and Gurusamy, Devikala and Levin, Noam and Kim, Sanghyun Peter and Sindiri, Sivasish and Gartner, Jared J and Prickett, Todd D and Parkhust, Maria and Lowery, Frank J and Goff, Stephanie L and Rosenberg, Steven A and Robbins, Paul},
  title = {Utilization of primary tumor samples for cancer neoantigen discovery},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-010993}
}
Kostenlos starten →